| Toxicology |
1 |
1 |
| Biologic Therapy |
0 |
0.87 |
| Nail |
0 |
0.99 |
| Psoriasis |
0 |
0.51 |
| Targeted Cancer Therapy |
0 |
0.98 |
| Cancer |
0 |
0.38 |
| Genomic Medicine |
0 |
0.27 |
| Paronychia |
0 |
0.26 |
| Skin and Soft Tissue Infection |
0 |
0.26 |
| Immunotherapy |
0 |
0.2 |
| Pyogenic Granuloma |
0 |
0.17 |
| Nucleoside Reverse Transcriptase Inhibitors |
0 |
0.09 |
| Onycholysis |
0 |
0.09 |
| Orbit |
0 |
0.09 |
| Antiretroviral Therapy for HIV Infection |
0 |
0.08 |
| HIV Infection |
0 |
0.08 |
| Lichen Planus |
0 |
0.06 |
| Abscess |
0 |
0.03 |
| Antibiotics |
0 |
0.03 |
| Board Certification |
0 |
0.03 |
| Chemotherapy |
0 |
0.03 |
| Connecticut |
0 |
0.03 |
| Dermatomyositis |
0 |
0.03 |
| Fibroblast Growth Factor |
0 |
0.03 |
| Health Care Quality, Access, and Evaluation |
0 |
0.03 |
| Hemorrhage |
0 |
0.03 |
| Hospital |
0 |
0.03 |
| Immunomodulator |
0 |
0.03 |
| PubMed |
0 |
0.03 |
| Quality of Life |
0 |
0.03 |
| Receptors |
0 |
0.03 |
| Refractory |
0 |
0.03 |
| Social Determinants of Health |
0 |
0.03 |
| Texas |
0 |
0.03 |
| Tissue |
0 |
0.03 |
| Topical Antibiotics |
0 |
0.03 |